Lyell Immunopharma, Inc. LYEL
Lyell Immunopharma, Inc. (Nasdaq: LYEL) is an oncology drug developer. Its lead program, rondecabtagene autoleucel (ronde-cel), is in Phase 3 for relapsed/refractory large B-cell lymphoma (LBCL). Its next catalyst on record is ronde-cel: ASH 2026 presentation with updated data (December 2026).
Upcoming catalysts
- December 2026ronde-cel — ASH 2026 presentation with updated data
Updated data from the PiNACLE clinical trial are expected to be reported during the ASH 2026 presentation, including data in additional patients and longer follow-up.
Next further out: ronde-cel (PiNACLE-H2H trial) — progress update (H2 2026). 4 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| rondecabtagene autoleucel (ronde-cel) | relapsed/refractory large B-cell lymphoma, third-line or later (3L+) | cell therapy | Phase 3 |
| rondecabtagene autoleucel (ronde-cel) | relapsed/refractory large B-cell lymphoma, second-line (2L) | cell therapy | Phase 3 |
| LYL273 | relapsed/refractory metastatic colorectal cancer (mCRC) | cell therapy | Phase 2 |
| Undisclosed solid tumor CAR T-cell product | solid tumors | cell therapy | Pre-clinical |
Recent results and decisions
- Nov 4, 2026positive Updated PiNACLE pivotal trial data in 3L+ R/R LBCL showed 91% overall response rate, 77% complete response rate, 92% continued complete response at 6 months in 44 efficacy-evaluable patients.
The overall response rate was 91% and the complete response rate was 77% among 44 efficacy-evaluable patients in the 3L+ PiNACLE trial.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 oncology companies
- Astrazeneca PLC AZN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Revolution Medicines, Inc. RVMD
- Genmab A/S GMAB
- BioNTech SE BNTX
- Guardant Health, Inc. GH
- Exelixis, Inc. EXEL
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.